Skip to content
Federal Election, Medical Health Aged Care

Over one million Australians deserve better access and lower costs for ADHD treatment

Royal Australian College of GPs 3 mins read

The Royal Australian College of GPs (RACGP) is calling for nationally uniform rules to ensure equitable access to attention deficit hyperactivity disorder (ADHD) treatment and medicines for the estimated one million plus Australians with ADHD during Neurodiversity Celebration Week.  

RACGP President Dr Michael Wright said: “ADHD is the most common neurodevelopmental condition in children and adolescents in Australia and while early diagnosis and treatment are crucial, many patients face long wait times and high costs for diagnosis and treatment.

“Currently, different states have different rules for prescribing stimulant medications.

“In some states, people can get treatment for ADHD from their GP, which means less frequent visits to the psychiatrist or paediatrician, while those living in other states experience delayed care due to long specialist waitlists.

“We recently  applauded the Western Australian Government for committing to the reforms we called for to allow specialist GPs to diagnose and prescribe stimulant medication for ADHD. In Queensland, skilled GPs can prescribe ADHD medications for four- to 18-year-olds, and we’re calling for better access to care for adults.

“But access to timely medical care shouldn’t be a postcode lottery. GPs can and should be able to do more for their patients with ADHD, and the Federal Government recognises this – we welcomed the Federal Government’s support for nationally consistent rules for ADHD prescribing last year.

“Now in the lead up to the federal election, we’re calling for all political parties to commit to increasing the number of medicines GPs can prescribe, including essential medicines for people with ADHD.

“Our plan for accessible, affordable general practice care for all Australia also calls for higher patient Medicare rebates for longer consultations, which people with complex health issues like ADHD need.

“This will halve out-of-pocket costs for and improve access to care for patients.

“When skilled GPs can better support people living with ADHD and prescribe medicines, it reduces financial barriers for patients, improves health outcomes and eases pressure on the health system.”

New South Wales Mid Coast mother Suzanne Grobke has a 12-year-old daughter with ADHD, oppositional defiant disorder (ODD) and suspected autism.

To access the medicine her daughter needs, they face an eight-hour return trip to Sydney and time off work every three months.

“My daughter was diagnosed when she was about three and a half, and we see a pediatrician in Sydney because it was up to a two year wait to see someone regionally,” she said.

“She has displayed suicidal thoughts and self-harmed, she is on anxiety meds, anti-psychotics, sleeping meds and Ritalin. It’s a lot for a 12-year-old.

“We travel to Sydney every three months, because even though our GP here can prescribe her other meds, the pediatrician is the only one who can prescribe the Ritalin she needs.

“The out-of-pocket expenses for psychiatrists, occupational therapy and medical appointments, often weekly, on top of these trips to Sydney, make it hard.”

Suzanne said parents need access to affordable care for kids with ADHD, and if GPs could prescribe stimulant medication, it would reduce costs, and children would get the support and treatment they need faster, closer to home.

“If my GP up here could prescribe the right medicines, it would make it so much easier,” she said.

“A good GP who knows your child, will know what your child needs and can help them straight away, not six or twelve months down the track when things have gotten worse.”

The AADPA website shows the different rules for prescribing stimulant medications for ADHD in every state and territory.   

~ENDS


About us:

The Royal Australian College of General Practitioners (RACGP) is the peak representative organisation for general practice, the backbone of Australia’s health system. We set the standards for general practice, facilitate lifelong learning for GPs, connect the general practice community, and advocate for better health and wellbeing for all Australians.

Visit www.racgp.org.au. To unsubscribe from RACGP media releases, click here.


Contact details:

John Ronan
Media Adviser

Ally Francis
Media Adviser

Stuart Winthrope
Media Officer

Contact: 03 8699 0992[email protected]

Follow us on Twitter: @RACGP and Facebook.

Media

More from this category

  • Medical Health Aged Care
  • 26/04/2025
  • 08:04
Monash University

The power of pets in reducing loneliness and social isolation for at-risk groups

A new pilot program funded by the National Centre for Healthy Ageing (NCHA), a partnership between Monash University and Peninsula Health, is the first to use a shared interest in pets to help build connections between young and older adults to reduce loneliness and social isolation. Social isolation and loneliness stem from a reduced sense of belonging, due to a lack of social connections, and can lead to detrimental effects on physical health and cognitive decline. These experiences have been exacerbated due to the COVID-19 pandemic. Two of the most impacted groups in relation to social isolation and loneliness are…

  • Medical Health Aged Care
  • 25/04/2025
  • 18:11
Elixir Medical Corporation

Elixir Medical Announces First Use of LithiX Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in Asia Pacific at Cardiac Vascular Sentral Kuala Lumpur (CVSKL), Malaysia

First cases completed by Dr. Tamil Selvan Muthusamy, MD, and Dr. Rosli Mohd Ali, MD, and transmitted live at TCTAP Congress in Seoul, Korea.Novel IVL technology designed to deliver calcium fragmentation for treatment of moderate to severely calcified coronary artery lesions without requiring an external energy source.MILPITAS, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced the first clinical use of its LithiX™ Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in the Asia Pacific region, marking a significant milestone in the device's global introduction. The procedures were successfully performed…

  • Medical Health Aged Care
  • 25/04/2025
  • 09:59
Monash University

Repurposed diabetes drug can reduce pain for those with knee arthritis and overweight or obesity: study

A common diabetes drug can reduce the pain of people with knee osteoarthritis and overweight or obesity, possibly delaying the need for knee replacements, Monash University-led research has found. Metformin, which is commonly prescribed to treat type 2 diabetes, reduced knee arthritis pain over six months in a clinical trial published in JAMA. The randomised clinical trial looked at whether metformin, compared to a placebo, reduced knee pain in patients withsymptomatic knee osteoarthritis (knee OA) andoverweight or obesity. The research was performed entirely as a community-based study using telehealth. Some of the 107 participants with pain from knee osteoarthritis (73…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.